drugset / Trial / NCT07610538
Low-dose Interleukin-2 After Myocardial Infarction to Investigate Effects on Tissue-resident Regulatory T Cells
Recruiting
24 enrolled
Cambridge University Hospitals NHS Foundation Trust
Royal Papworth Hospital · collab
RandomizedParallel-groupOpen-labelBasic science
Summary
The primary goals of this study are to compare the differences in tissue-resident Treg gene signature for activation, proliferation, and suppressive function using single-cell/-nucleus RNA sequencing in patients treated with ld-IL-2 compared to control grouped by individual tissue beds from in and around the heart. Additionally, tissue-resident Tregs will be compared to peripheral blood Tregs from the same patient to assess the differential effect of ld-IL-2 on the two compartments.
Timeline
- Start
- 2026-03-31
- Primary completion
- 2028-11-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 1.5e+06 iu | Subcutaneous |
| Subject | aldesleukin | Protein / enzyme biologic | 2e+06 iu | Subcutaneous |